Press release
Anti-Inflammatory Biologics Market to Surpass $166.28 Billion by 2029 | Key Trends & Insights
Anti Inflammatory Biologics
How Will the Anti-Inflammatory Biologics Market Grow by 2025 in Terms of Size and Growth?
In recent times, there has been significant growth in the size of the anti-inflammatory biologics market. The market, which is projected to increase from $108.11 billion in 2024 to $118.02 billion in 2025,will witness a compound annual growth rate (CAGR) of 9.2%. This expansion during the historic phase is attributable to an escalation in arthritis cases, amplified awareness about autoimmune diseases, the introduction of novel biologics, enhancements in healthcare infrastructure, and an increase in regulatory approval rates.
What Are the Estimated Growth Rates for the Anti-Inflammatory Biologics Industry Through 2029?
In the forthcoming years, the market size for anti-inflammatory biologics is projected to experience robust growth, reaching $166.28 billion by 2029 with a compound annual growth rate (CAGR) of 9.0%. This market expansion in the forecast period is associated with factors such as increased adoption of biologics, growing demand for targeted therapies, a trend towards long-term remission preferred by patients, enhanced use of biomarkers for disease tracking, and a rising need for personalized medicine. Key trends for the forecast period comprise progress in biologic drug creation, formulation of oral biologics for inflammation, advancements in drug delivery systems influenced by technology, progress in biosimilars, and improvements in diagnostic tools.
Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report
What Are the Strategic Drivers Boosting Anti-Inflammatory Biologics Market Performance?
The escalating occurrence of arthritis is anticipated to fuel the expansion of the anti-inflammatory biologics market in the future. Arthritis denotes joint inflammation or swelling often accompanied by pain, stiffness, and a decrease in mobility, which usually intensifies with age. One of the main reasons for the increasing occurrence of arthritis is the surge in obesity rates. Higher body weight results in extra pressure on the joints, leading to inflammation and gradual joint wear. Anti-inflammatory biologics greatly benefit arthritis patients as they target certain components of the immune system to lower inflammation, slow down joint damage, alleviate symptoms, and enhance physical function and life quality for those with moderate to severe arthritis. As per the Office for Health Improvement and Disparities, a government department based in the UK, there was a rise from 17.0% in 2021 to 17.6% in 2022 in the percentage of people aged 16 and over with a long-term Musculoskeletal (MSK) condition such as arthritis or a persistent back or joint issue, reported in March 2023. Therefore, the escalating occurrence of arthritis is stimulating the expansion of the anti-inflammatory biologics market.
Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp
What Are the Segments in the Anti-Inflammatory Biologics Market?
The anti-inflammatory biologics market covered in this report is segmented -
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics
What Are the Key Adoption Trends in the Anti-Inflammatory Biologics Market?
Leading firms in the anti-inflammatory biologics sector are concentrating on the creation of innovative solutions like interleukin-6 (IL-6) receptor antagonists. These solutions are designed to specifically target chronic inflammatory diseases while minimizing side effects. IL-6 receptor antagonists are a type of biologic medication that work by blocking the IL-6 receptor, which then helps to lower inflammation and immune response in ailments like rheumatoid arthritis. An example of this came in February 2023 when Regeneron Pharmaceuticals Inc., a biotechnology company from the US, attained approval from the US Food and Drug Administration (FDA) for Kevzara. This solution is the only biologic treatment available for patients with polymyalgia rheumatica (PMR) who can't get adequate relief from corticosteroids. Kevzara is a fully human monoclonal antibody that inhibits the IL-6 receptor, consequently decreasing inflammation associated with PMR, an ailment that triggers muscle pain and stiffness primarily in elderly individuals. Unlike conventional steroids that can involve risks like osteoporosis and diabetes during prolonged usage, Kevzara offers a more specific, steroid-minimizing approach that bolsters improved patient results and long-term safety.
Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp
Which Companies Lead the Competitive Landscape of the Anti-Inflammatory Biologics Industry?
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.
Where Are the Key Anti-Inflammatory Biologics Market Opportunities by Region?
North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Reach Out to Us#
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-Inflammatory Biologics Market to Surpass $166.28 Billion by 2029 | Key Trends & Insights here
News-ID: 4156061 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Inhibitors
Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826
This latest report researches the industry structure,…
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market.
CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155
The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to…
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4…
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.
The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab…
